Literature DB >> 8864693

Inhibition by bertosamil of cardiac responses to pinacidil or Bay k 8644 in isolated dog atria and ventricles.

T Yonezawa1, Y Furukawa, M Kasama, Y Hoyano, H Imamura, S Chiba.   

Abstract

We investigated the effects of a novel bradycardiac agent, bertosamil (3-isobutyl-7-isopropyl-9,9-pentamethylene-3,7-diazabicyclo[3.3.1] nonane sesquihydrogenfumarate), on the sinus rate and atrial contractile force and the left ventricular contractile force in isolated, blood-perfused dog hearts and the blocking effects of bertosamil on the chronotropic and inotropic responses to pinacidil and Bay k 8644 (methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)- piridine-5-carboxylate). Bertosamil (0.1-100 nmol) caused transient positive, followed by continuous negative, chronotropic responses and positive inotropic responses in atria, and increased the left ventricular contractile force. Neither propranolol nor atropine affected the cardiac responses to bertosamil. Bertosamil (3-100 nmol) dose dependently attenuated the negative chronotropic and inotropic responses to pinacidil but not to acetylcholine. Bertosamil at a high dose attenuated the positive cardiac responses to Bay k 8644, norepinephrine and isoproterenol. These results suggest that bertosamil inhibits negative cardiac responses mediated by an ATP-sensitive K+ channel but not an acetylcholine muscarinic receptor and, at a high dose, attenuates the L-type Ca2+ channel-mediated positive cardiac responses in isolated dog hearts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864693     DOI: 10.1016/0014-2999(96)00322-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  1 in total

1.  Bertosamil blocks HERG potassium channels in their open and inactivated states.

Authors:  Edgar Zitron; Christoph A Karle; Gunnar Wendt-Nordahl; Sven Kathöfer; Wei Zhang; Dierk Thomas; Slawomir Weretka; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.